A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies

Michelle A. Fanale, Andres Forero-Torres, Joseph D Rosenblatt, Ranjana H. Advani, Anna R. Franklin, Dana A. Kennedy, Tae H. Han, Eric L. Sievers, Nancy L. Bartlett

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

Purpose: The antibody-drug conjugate (ADC) brentuximab vedotin comprises a CD30-directed antibody covalently attached to the potent antimicrotubule agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. This study explored the safety, maximum-tolerated dose (MTD), and activity of weekly dosing of brentuximab vedotin in patients with relapsed or refractory CD30-positive hematologic malignancies. Experimental Design: In this phase I dose-escalation study, brentuximab vedotin was administered intravenously on Days 1, 8, and 15, of each 28-day cycle at doses ranging from 0.4 to 1.4 mg/kg. Forty-four patients were enrolled: 38 with Hodgkin lymphoma, five with systemic anaplastic large cell lymphoma, and one with peripheral T-cell lymphoma not otherwise specified. Doses were escalated in increments of 0.2 mg/kg until dose-limiting toxicity (DLT) was observed. Patients were monitored for antitherapeutic antibodies and pharmacokinetic parameters. Antitumor assessments were carried out every two cycles. Results: The MTD was 1.2 mg/kg. The most commonadverse events were peripheral sensory neuropathy, fatigue, nausea, diarrhea, arthralgia, and pyrexia; and the majority of events were mild to moderate in severity. Tumor regression occurred in 85% of patients and the overall objective response rate was 59% (n = 24), with 34% (n = 14) complete remissions. The median duration of response was not reached at a median follow-up of 45 weeks on study. Conclusions: Weekly administration of brentuximab vedotin resulted in tumor regression and durable remissions in patients with CD30-positive malignancies. This ADC was associated with manageable toxicity, including peripheral neuropathy. Further study in CD30-positive malignancies is warranted.

Original languageEnglish
Pages (from-to)248-255
Number of pages8
JournalClinical Cancer Research
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2012

Fingerprint

Hematologic Neoplasms
Maximum Tolerated Dose
Antibodies
Peripheral Nervous System Diseases
Neoplasms
Peripheral T-Cell Lymphoma
Anaplastic Large-Cell Lymphoma
Arthralgia
Hodgkin Disease
Pharmaceutical Preparations
Nausea
Fatigue
Diarrhea
Peptide Hydrolases
Research Design
Fever
Pharmacokinetics
cAC10-vcMMAE
Safety

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. / Fanale, Michelle A.; Forero-Torres, Andres; Rosenblatt, Joseph D; Advani, Ranjana H.; Franklin, Anna R.; Kennedy, Dana A.; Han, Tae H.; Sievers, Eric L.; Bartlett, Nancy L.

In: Clinical Cancer Research, Vol. 18, No. 1, 01.01.2012, p. 248-255.

Research output: Contribution to journalArticle

Fanale, MA, Forero-Torres, A, Rosenblatt, JD, Advani, RH, Franklin, AR, Kennedy, DA, Han, TH, Sievers, EL & Bartlett, NL 2012, 'A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies', Clinical Cancer Research, vol. 18, no. 1, pp. 248-255. https://doi.org/10.1158/1078-0432.CCR-11-1425
Fanale, Michelle A. ; Forero-Torres, Andres ; Rosenblatt, Joseph D ; Advani, Ranjana H. ; Franklin, Anna R. ; Kennedy, Dana A. ; Han, Tae H. ; Sievers, Eric L. ; Bartlett, Nancy L. / A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. In: Clinical Cancer Research. 2012 ; Vol. 18, No. 1. pp. 248-255.
@article{8aeadf8bc6a0426e80537f0e62b633d5,
title = "A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies",
abstract = "Purpose: The antibody-drug conjugate (ADC) brentuximab vedotin comprises a CD30-directed antibody covalently attached to the potent antimicrotubule agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. This study explored the safety, maximum-tolerated dose (MTD), and activity of weekly dosing of brentuximab vedotin in patients with relapsed or refractory CD30-positive hematologic malignancies. Experimental Design: In this phase I dose-escalation study, brentuximab vedotin was administered intravenously on Days 1, 8, and 15, of each 28-day cycle at doses ranging from 0.4 to 1.4 mg/kg. Forty-four patients were enrolled: 38 with Hodgkin lymphoma, five with systemic anaplastic large cell lymphoma, and one with peripheral T-cell lymphoma not otherwise specified. Doses were escalated in increments of 0.2 mg/kg until dose-limiting toxicity (DLT) was observed. Patients were monitored for antitherapeutic antibodies and pharmacokinetic parameters. Antitumor assessments were carried out every two cycles. Results: The MTD was 1.2 mg/kg. The most commonadverse events were peripheral sensory neuropathy, fatigue, nausea, diarrhea, arthralgia, and pyrexia; and the majority of events were mild to moderate in severity. Tumor regression occurred in 85{\%} of patients and the overall objective response rate was 59{\%} (n = 24), with 34{\%} (n = 14) complete remissions. The median duration of response was not reached at a median follow-up of 45 weeks on study. Conclusions: Weekly administration of brentuximab vedotin resulted in tumor regression and durable remissions in patients with CD30-positive malignancies. This ADC was associated with manageable toxicity, including peripheral neuropathy. Further study in CD30-positive malignancies is warranted.",
author = "Fanale, {Michelle A.} and Andres Forero-Torres and Rosenblatt, {Joseph D} and Advani, {Ranjana H.} and Franklin, {Anna R.} and Kennedy, {Dana A.} and Han, {Tae H.} and Sievers, {Eric L.} and Bartlett, {Nancy L.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1158/1078-0432.CCR-11-1425",
language = "English",
volume = "18",
pages = "248--255",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies

AU - Fanale, Michelle A.

AU - Forero-Torres, Andres

AU - Rosenblatt, Joseph D

AU - Advani, Ranjana H.

AU - Franklin, Anna R.

AU - Kennedy, Dana A.

AU - Han, Tae H.

AU - Sievers, Eric L.

AU - Bartlett, Nancy L.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Purpose: The antibody-drug conjugate (ADC) brentuximab vedotin comprises a CD30-directed antibody covalently attached to the potent antimicrotubule agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. This study explored the safety, maximum-tolerated dose (MTD), and activity of weekly dosing of brentuximab vedotin in patients with relapsed or refractory CD30-positive hematologic malignancies. Experimental Design: In this phase I dose-escalation study, brentuximab vedotin was administered intravenously on Days 1, 8, and 15, of each 28-day cycle at doses ranging from 0.4 to 1.4 mg/kg. Forty-four patients were enrolled: 38 with Hodgkin lymphoma, five with systemic anaplastic large cell lymphoma, and one with peripheral T-cell lymphoma not otherwise specified. Doses were escalated in increments of 0.2 mg/kg until dose-limiting toxicity (DLT) was observed. Patients were monitored for antitherapeutic antibodies and pharmacokinetic parameters. Antitumor assessments were carried out every two cycles. Results: The MTD was 1.2 mg/kg. The most commonadverse events were peripheral sensory neuropathy, fatigue, nausea, diarrhea, arthralgia, and pyrexia; and the majority of events were mild to moderate in severity. Tumor regression occurred in 85% of patients and the overall objective response rate was 59% (n = 24), with 34% (n = 14) complete remissions. The median duration of response was not reached at a median follow-up of 45 weeks on study. Conclusions: Weekly administration of brentuximab vedotin resulted in tumor regression and durable remissions in patients with CD30-positive malignancies. This ADC was associated with manageable toxicity, including peripheral neuropathy. Further study in CD30-positive malignancies is warranted.

AB - Purpose: The antibody-drug conjugate (ADC) brentuximab vedotin comprises a CD30-directed antibody covalently attached to the potent antimicrotubule agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. This study explored the safety, maximum-tolerated dose (MTD), and activity of weekly dosing of brentuximab vedotin in patients with relapsed or refractory CD30-positive hematologic malignancies. Experimental Design: In this phase I dose-escalation study, brentuximab vedotin was administered intravenously on Days 1, 8, and 15, of each 28-day cycle at doses ranging from 0.4 to 1.4 mg/kg. Forty-four patients were enrolled: 38 with Hodgkin lymphoma, five with systemic anaplastic large cell lymphoma, and one with peripheral T-cell lymphoma not otherwise specified. Doses were escalated in increments of 0.2 mg/kg until dose-limiting toxicity (DLT) was observed. Patients were monitored for antitherapeutic antibodies and pharmacokinetic parameters. Antitumor assessments were carried out every two cycles. Results: The MTD was 1.2 mg/kg. The most commonadverse events were peripheral sensory neuropathy, fatigue, nausea, diarrhea, arthralgia, and pyrexia; and the majority of events were mild to moderate in severity. Tumor regression occurred in 85% of patients and the overall objective response rate was 59% (n = 24), with 34% (n = 14) complete remissions. The median duration of response was not reached at a median follow-up of 45 weeks on study. Conclusions: Weekly administration of brentuximab vedotin resulted in tumor regression and durable remissions in patients with CD30-positive malignancies. This ADC was associated with manageable toxicity, including peripheral neuropathy. Further study in CD30-positive malignancies is warranted.

UR - http://www.scopus.com/inward/record.url?scp=84855465227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855465227&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-1425

DO - 10.1158/1078-0432.CCR-11-1425

M3 - Article

C2 - 22080439

AN - SCOPUS:84855465227

VL - 18

SP - 248

EP - 255

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1

ER -